Changes
in deferred revenue from contract liabilities follows:
Schedule of Changes in Deferred Revenue from Contract Liabilities
| | |
2026 | | |
2025 | |
| Balance January 1, | |
$ | 8,054 | | |
$ | 6,255 | |
| Beginning balance | |
$ | 8,054 | | |
$ | 6,255 | |
| | |
| | | |
| | |
| Deferral of revenue (1) | |
| 15,828 | | |
| 2,939 | |
| Revenue recognized | |
| (5,682 | ) | |
| (2,822 | ) |
| Balance June 30, | |
$ | 18,200 | | |
$ | 6,372 | |
| Ending balance | |
$ | 18,200 | | |
$ | 6,372 | |
| (1) |
As
of June 30, 2026, deferral of revenue includes (i) $13.3 million in upfront consideration related to the license agreement with NexGel (refer to Note 17 – License and Distribution Agreements for additional information) and (ii) $2.4 million as of June 30, 2026 resulting from payments received in
advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance
is completed. Deferral of revenue includes $1,208 as of June 30, 2025 resulting from payments received in advance of performance
under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed. |
|